Oct 27, 2021
Immutep Quarterly Activities Report
Sep 30, 2021
Immutep to present Phase II TACTI-002 data at SITC 2021
Sep 28, 2021
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
Immutep to Present at Healthcare Investor Conferences
Sep 20, 2021
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
Sep 01, 2021
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Aug 30, 2021
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Aug 26, 2021
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Aug 04, 2021
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
Jul 13, 2021
Jul 05, 2021
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
Jun 21, 2021
Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings
